Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLCN2 | P51788 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | F2R | P25116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494676 | 0.86 | PTPN1 (0.47) | KMT2AALDH1A1LMNAMEN1PTPN1 | |
| SCHEMBL12985387 | 0.80 | ALDH1A1 (0.41) | CLCN2KMT2AALDH1A1LMNAFOLH1 | |
| SCHEMBL9650318 | 0.78 | CYP2C19 (0.46) | CLCN2KMT2AALDH1A1FOLH1POLB | |
| SCHEMBL8114342 | 0.77 | CLCN2 (0.42) | CLCN2KMT2AALDH1A1FOLH1POLB | |
| SCHEMBL10276952 | 0.76 | CLCN2 (0.43) | CLCN2KMT2AALDH1A1POLBHTT | |
| SCHEMBL6983533 | 0.75 | CLCN2 (0.39) | CLCN2KMT2AALDH1A1FOLH1POLB | |
| Hydrogen Peroxide SCHEMBL11781319 | 0.74 | CLCN2 (0.49) | CLCN2ALDH1A1LMNAFOLH1HTT | |
| SCHEMBL3364147 | 0.73 | CLCN2 (0.41) | CLCN2KMT2AALDH1A1FOLH1HTT | |
| Benzene SCHEMBL28132336 | 0.72 | LMNA (0.53) | CLCN2KMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL390944 | 0.72 | LMNA (0.53) | CLCN2KMT2AALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | CLCN2 2983/4885KMT2A 952/4885ALDH1A1 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.